Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies and antibody radiation conjugates aimed at improving outcomes for cancer patients with unmet needs. The company focuses on expanding its pipeline of targeted radiotherapies for blood cancers and solid tumors, leveraging its proprietary Actinium-225 technology platform and collaborations with institutions like the NCI. Its key products include Actimab-A, Iomab-B, and Iomab-ACT, with ongoing clinical trials and strategic partnerships to advance its innovative therapies.
Industries
Nr. of Employees
small (1-50)
Actinium Pharmaceuticals, Inc.
100 Park Avenue, 23rd Floor, New York, NY 10017
Patents
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
US-12133849-B2
View DetailsAnti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-11912780-B2
View Details
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
US-12133849-B2
View DetailsAnti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
US-11912780-B2
View DetailsProducts
Iomab-B (CD45 targeted radiotherapeutic)
A CD45-targeted radiotherapeutic developed as an induction and conditioning agent to enable bone marrow transplantation by depleting malignant and marrow cells expressing the CD45 antigen; studied in a pivotal Phase 3 trial reporting improved access to transplant and efficacy endpoints.
Iomab-ACT (targeted lymphodepletion for CAR‑T and gene therapy)
A targeted lymphodepletion conditioning program using an anti-CD45 antibody labeled with a beta-emitter at lower, non‑myeloablative doses to achieve lymphodepletion prior to CAR‑T or gene therapy with the goal of improving access and outcomes.
Actimab-A (CD33-targeted radiotherapeutic)
A CD33-targeted antibody-radioconjugate in clinical development for relapsed/refractory acute myeloid leukemia (AML), studied in combination with chemotherapy and targeted agents to exploit synergistic mechanisms and achieve deep responses.
ATNM-400 (non‑PSMA Ac-225 solid tumor candidate)
A development-stage radiotherapeutic described as a first-in-class non‑PSMA prostate cancer therapy utilizing an alpha-emitting radionuclide warhead for targeted solid tumor applications.
Iomab-B (CD45 targeted radiotherapeutic)
A CD45-targeted radiotherapeutic developed as an induction and conditioning agent to enable bone marrow transplantation by depleting malignant and marrow cells expressing the CD45 antigen; studied in a pivotal Phase 3 trial reporting improved access to transplant and efficacy endpoints.
Iomab-ACT (targeted lymphodepletion for CAR‑T and gene therapy)
A targeted lymphodepletion conditioning program using an anti-CD45 antibody labeled with a beta-emitter at lower, non‑myeloablative doses to achieve lymphodepletion prior to CAR‑T or gene therapy with the goal of improving access and outcomes.
Actimab-A (CD33-targeted radiotherapeutic)
A CD33-targeted antibody-radioconjugate in clinical development for relapsed/refractory acute myeloid leukemia (AML), studied in combination with chemotherapy and targeted agents to exploit synergistic mechanisms and achieve deep responses.
ATNM-400 (non‑PSMA Ac-225 solid tumor candidate)
A development-stage radiotherapeutic described as a first-in-class non‑PSMA prostate cancer therapy utilizing an alpha-emitting radionuclide warhead for targeted solid tumor applications.
Services
Collaborative preclinical and clinical research partnerships to develop and evaluate targeted radiotherapeutics, including cooperative research agreements with national clinical trial networks and academic medical centers.
Cyclotron-based production and supply of Ac-225 produced via irradiated radium targets, with end-to-end processing, QA/QC and batch reporting intended to support clinical and development programs.
Clinical program planning, trial execution and reporting support for oncology radiotherapeutics across early- and late-stage studies, including management of endpoints, safety reporting and investigator collaborations.
Collaborative preclinical and clinical research partnerships to develop and evaluate targeted radiotherapeutics, including cooperative research agreements with national clinical trial networks and academic medical centers.
Cyclotron-based production and supply of Ac-225 produced via irradiated radium targets, with end-to-end processing, QA/QC and batch reporting intended to support clinical and development programs.
Clinical program planning, trial execution and reporting support for oncology radiotherapeutics across early- and late-stage studies, including management of endpoints, safety reporting and investigator collaborations.
Expertise Areas
- Targeted radiotherapy development
- Antibody–radiation conjugate (ARC) R&D
- Radiochemistry and isotope purification
- Cyclotron-based radioisotope manufacturing
Key Technologies
- Antibody–radiation conjugates
- Alpha-emitter therapy (Ac-225)
- Cyclotron-based Ac-225 production
- Iodine-131 and Lutetium-177 labeling